Informa Life Sciences is part of the Knowledge and Networking Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

Informa

14 - 15 March 2018
Novotel Amsterdam City,
Amsterdam

Translating the Human Microbiome into Commercially Viable Medicines

Industry Insights. Regulatory Feedback. Innovative Solutions

Present a Scientific Poster at Microbiome Therapeutics 2018


Showcase your company's latest research by presenting a poster at Microbiome Therapeutics 2018. All posters will be displayed in the exhibition hall throughout the event.

Please note that all poster presenters must be registered attendees. The deadline to submit your abstract is Friday 23rd February 2018.

Webinars. Webinars. Webinars.

WEBINAR: The Commercial Considerations of Microbiome-Based Therapeutics [Tuesday 5th December | 3-4pm GMT]

The advent of microbiome-based therapeutics will offer physicians and their patients novel treatment options. They will be very different in their composition when compared to current therapies that are all based on small and large molecules.

Join JP Benya, Vice President, Commercial at Assembly Biosciences for this webinar as he explores what the regulatory considerations, customer expectations, messaging implications, and other factors involved in launching these therapeutics might be...

JP will discuss: What are the key issues that commercial teams (marketing, market research, sales, managed care, etc.) will need to address to ensure that the therapeutic promise of these agents translates into commercial success?

Plus, ask your questions in a live Q&A with JP Benya after the session!

WEBINAR: Solving the Metagenome Assembly Problem with Hi-C [Wednesday 6th December | 4-5pm GMT]

Chromosome Conformation Capture tools like Hi-C directly indicate which DNA sequences originated from the same cells in a mixed population. This enables the assembly of numerous high-quality de novo genomes (with plasmids) without culturing from a single microbiome sample.

Phase Genomics has developed a rapid, kit-based  platform that greatly improves microbiome research efforts and shortens the path to microbial discovery. 

Join Ivan Liachko, Co-founder & CEO at Phase Genomics as he discusses; How Hi-C works; How Hi-C data can be used to deconvolve metagenomes; What kinds of information you can glean from this data (case studies); And how this technology can be applied to your favorite samples.

Plus, ask your questions in a live Q&A with Ivan after the session!

Microbiome industry multiplication...

73%
The expected microbiome therapeutics market growth rate between 2015 and 2030
£329.7m
The expected microbiome therapeutics market value by 2025
170+
Microbiome therapeutics in early phase development